Benefits of Sharbat Afsanteen in Poly Cystic Ovarian Disease

Effect of Sharbat Afsanteen in Poly Cystic Ovarian Disease - An Open Observational Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/017970

Enrollment

Registered

2019-03-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N832- Other and unspecified ovarian cysts

Interventions

Intervention1: Not applicable: Not applicable Intervention2: NA: NA Intervention3: Sharbat Afsanteen: 25 ml twice a day for 15 days for 3 cycles Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients both unmarried and married between the age group of 18 to 35 years. 2.History of irregular periods like oligomenorrhea or amenorrhoea with PCOD ( >35days to 6 months) 3.Presence of Polycystic ovaries on Ultrasound scan

Exclusion criteria

Exclusion criteria: 1.Systemic and endocrinal diseases like Hypertension, Diabetes mellitus and thyroid dysfunction 2.Patients on hormonal treatment during the last 3 months. 3.Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Regularisation of mestruationTimepoint: Regularisation of mestruation	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactZainab Zubair

Rajiv Gandhi University of Health Sciences

drtabassum.nium@gmail.com7349074142

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026